nodes	percent_of_prediction	percent_of_DWPC	metapath
Palonosetron—CYP1A2—Pentoxifylline—systemic scleroderma	0.171	0.32	CbGbCtD
Palonosetron—CYP1A2—Leflunomide—systemic scleroderma	0.163	0.305	CbGbCtD
Palonosetron—CYP2D6—Captopril—systemic scleroderma	0.105	0.197	CbGbCtD
Palonosetron—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0528	0.0988	CbGbCtD
Palonosetron—CYP3A4—Prednisone—systemic scleroderma	0.0422	0.079	CbGbCtD
Palonosetron—HTR3A—myenteric nerve plexus—systemic scleroderma	0.0254	0.789	CbGeAlD
Palonosetron—HTR3A—digestive system—systemic scleroderma	0.00193	0.0598	CbGeAlD
Palonosetron—HTR3A—lung—systemic scleroderma	0.00161	0.0499	CbGeAlD
Palonosetron—CYP1A2—digestive system—systemic scleroderma	0.000994	0.0308	CbGeAlD
Palonosetron—CYP1A2—lung—systemic scleroderma	0.00083	0.0258	CbGeAlD
Palonosetron—CYP3A4—digestive system—systemic scleroderma	0.00072	0.0223	CbGeAlD
Palonosetron—CYP2D6—digestive system—systemic scleroderma	0.000708	0.022	CbGeAlD
Palonosetron—Anorexia—Mycophenolic acid—systemic scleroderma	0.000637	0.00147	CcSEcCtD
Palonosetron—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.000637	0.00147	CcSEcCtD
Palonosetron—Insomnia—Leflunomide—systemic scleroderma	0.000634	0.00146	CcSEcCtD
Palonosetron—Abdominal distension—Prednisone—systemic scleroderma	0.000633	0.00146	CcSEcCtD
Palonosetron—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.000633	0.00146	CcSEcCtD
Palonosetron—Paraesthesia—Leflunomide—systemic scleroderma	0.000629	0.00145	CcSEcCtD
Palonosetron—Anaphylactoid reaction—Methotrexate—systemic scleroderma	0.000628	0.00145	CcSEcCtD
Palonosetron—Arthralgia—Lisinopril—systemic scleroderma	0.000628	0.00145	CcSEcCtD
Palonosetron—Myalgia—Lisinopril—systemic scleroderma	0.000628	0.00145	CcSEcCtD
Palonosetron—Anxiety—Lisinopril—systemic scleroderma	0.000626	0.00144	CcSEcCtD
Palonosetron—Dyspnoea—Leflunomide—systemic scleroderma	0.000625	0.00144	CcSEcCtD
Palonosetron—Hypotension—Mycophenolic acid—systemic scleroderma	0.000625	0.00144	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000624	0.00144	CcSEcCtD
Palonosetron—Discomfort—Lisinopril—systemic scleroderma	0.000621	0.00143	CcSEcCtD
Palonosetron—Dyspepsia—Leflunomide—systemic scleroderma	0.000617	0.00142	CcSEcCtD
Palonosetron—Vomiting—Mometasone—systemic scleroderma	0.000616	0.00142	CcSEcCtD
Palonosetron—Dry mouth—Lisinopril—systemic scleroderma	0.000614	0.00142	CcSEcCtD
Palonosetron—Rash—Mometasone—systemic scleroderma	0.00061	0.00141	CcSEcCtD
Palonosetron—Asthenia—Captopril—systemic scleroderma	0.00061	0.00141	CcSEcCtD
Palonosetron—Dermatitis—Mometasone—systemic scleroderma	0.00061	0.00141	CcSEcCtD
Palonosetron—Decreased appetite—Leflunomide—systemic scleroderma	0.000609	0.00141	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000609	0.00141	CcSEcCtD
Palonosetron—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000607	0.0014	CcSEcCtD
Palonosetron—Headache—Mometasone—systemic scleroderma	0.000607	0.0014	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000605	0.0014	CcSEcCtD
Palonosetron—Insomnia—Mycophenolic acid—systemic scleroderma	0.000605	0.0014	CcSEcCtD
Palonosetron—Fatigue—Leflunomide—systemic scleroderma	0.000604	0.00139	CcSEcCtD
Palonosetron—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000602	0.00139	CcSEcCtD
Palonosetron—Pruritus—Captopril—systemic scleroderma	0.000602	0.00139	CcSEcCtD
Palonosetron—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.0006	0.00139	CcSEcCtD
Palonosetron—Pain—Leflunomide—systemic scleroderma	0.000599	0.00138	CcSEcCtD
Palonosetron—Constipation—Leflunomide—systemic scleroderma	0.000599	0.00138	CcSEcCtD
Palonosetron—Infection—Lisinopril—systemic scleroderma	0.000598	0.00138	CcSEcCtD
Palonosetron—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000598	0.00138	CcSEcCtD
Palonosetron—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000596	0.00138	CcSEcCtD
Palonosetron—Somnolence—Mycophenolic acid—systemic scleroderma	0.000594	0.00137	CcSEcCtD
Palonosetron—Shock—Lisinopril—systemic scleroderma	0.000593	0.00137	CcSEcCtD
Palonosetron—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000589	0.00136	CcSEcCtD
Palonosetron—Tachycardia—Lisinopril—systemic scleroderma	0.000588	0.00136	CcSEcCtD
Palonosetron—Body temperature increased—Azathioprine—systemic scleroderma	0.000587	0.00135	CcSEcCtD
Palonosetron—Abdominal pain—Azathioprine—systemic scleroderma	0.000587	0.00135	CcSEcCtD
Palonosetron—Skin disorder—Lisinopril—systemic scleroderma	0.000585	0.00135	CcSEcCtD
Palonosetron—Diarrhoea—Captopril—systemic scleroderma	0.000582	0.00134	CcSEcCtD
Palonosetron—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000581	0.00134	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000577	0.00133	CcSEcCtD
Palonosetron—Fatigue—Mycophenolic acid—systemic scleroderma	0.000576	0.00133	CcSEcCtD
Palonosetron—Nausea—Mometasone—systemic scleroderma	0.000575	0.00133	CcSEcCtD
Palonosetron—Anorexia—Lisinopril—systemic scleroderma	0.000574	0.00132	CcSEcCtD
Palonosetron—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000573	0.00132	CcSEcCtD
Palonosetron—Constipation—Mycophenolic acid—systemic scleroderma	0.000572	0.00132	CcSEcCtD
Palonosetron—Pain—Mycophenolic acid—systemic scleroderma	0.000572	0.00132	CcSEcCtD
Palonosetron—Hyperglycaemia—Prednisone—systemic scleroderma	0.000567	0.00131	CcSEcCtD
Palonosetron—Hypotension—Lisinopril—systemic scleroderma	0.000563	0.0013	CcSEcCtD
Palonosetron—Dizziness—Captopril—systemic scleroderma	0.000562	0.0013	CcSEcCtD
Palonosetron—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.00056	0.00129	CcSEcCtD
Palonosetron—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000558	0.00129	CcSEcCtD
Palonosetron—Abdominal pain—Leflunomide—systemic scleroderma	0.000554	0.00128	CcSEcCtD
Palonosetron—Body temperature increased—Leflunomide—systemic scleroderma	0.000554	0.00128	CcSEcCtD
Palonosetron—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.00055	0.00127	CcSEcCtD
Palonosetron—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.00055	0.00127	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000549	0.00127	CcSEcCtD
Palonosetron—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000549	0.00127	CcSEcCtD
Palonosetron—Hypersensitivity—Azathioprine—systemic scleroderma	0.000547	0.00126	CcSEcCtD
Palonosetron—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000547	0.00126	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000547	0.00126	CcSEcCtD
Palonosetron—Insomnia—Lisinopril—systemic scleroderma	0.000545	0.00126	CcSEcCtD
Palonosetron—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000544	0.00126	CcSEcCtD
Palonosetron—Paraesthesia—Lisinopril—systemic scleroderma	0.000541	0.00125	CcSEcCtD
Palonosetron—Vomiting—Captopril—systemic scleroderma	0.000541	0.00125	CcSEcCtD
Palonosetron—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000538	0.00124	CcSEcCtD
Palonosetron—Dyspnoea—Lisinopril—systemic scleroderma	0.000537	0.00124	CcSEcCtD
Palonosetron—Rash—Captopril—systemic scleroderma	0.000536	0.00124	CcSEcCtD
Palonosetron—Dermatitis—Captopril—systemic scleroderma	0.000536	0.00124	CcSEcCtD
Palonosetron—Somnolence—Lisinopril—systemic scleroderma	0.000535	0.00124	CcSEcCtD
Palonosetron—Headache—Captopril—systemic scleroderma	0.000533	0.00123	CcSEcCtD
Palonosetron—Dyspepsia—Lisinopril—systemic scleroderma	0.00053	0.00122	CcSEcCtD
Palonosetron—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000529	0.00122	CcSEcCtD
Palonosetron—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000529	0.00122	CcSEcCtD
Palonosetron—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000528	0.00122	CcSEcCtD
Palonosetron—Infection—Mycophenolate mofetil—systemic scleroderma	0.000524	0.00121	CcSEcCtD
Palonosetron—Decreased appetite—Lisinopril—systemic scleroderma	0.000524	0.00121	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00052	0.0012	CcSEcCtD
Palonosetron—Fatigue—Lisinopril—systemic scleroderma	0.000519	0.0012	CcSEcCtD
Palonosetron—Shock—Mycophenolate mofetil—systemic scleroderma	0.000519	0.0012	CcSEcCtD
Palonosetron—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000517	0.00119	CcSEcCtD
Palonosetron—Hypersensitivity—Leflunomide—systemic scleroderma	0.000516	0.00119	CcSEcCtD
Palonosetron—Constipation—Lisinopril—systemic scleroderma	0.000515	0.00119	CcSEcCtD
Palonosetron—Pain—Lisinopril—systemic scleroderma	0.000515	0.00119	CcSEcCtD
Palonosetron—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000515	0.00119	CcSEcCtD
Palonosetron—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000513	0.00118	CcSEcCtD
Palonosetron—Bradycardia—Prednisone—systemic scleroderma	0.000513	0.00118	CcSEcCtD
Palonosetron—Diarrhoea—Azathioprine—systemic scleroderma	0.000508	0.00117	CcSEcCtD
Palonosetron—Nausea—Captopril—systemic scleroderma	0.000505	0.00117	CcSEcCtD
Palonosetron—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000503	0.00116	CcSEcCtD
Palonosetron—Asthenia—Leflunomide—systemic scleroderma	0.000503	0.00116	CcSEcCtD
Palonosetron—Pruritus—Leflunomide—systemic scleroderma	0.000496	0.00114	CcSEcCtD
Palonosetron—Connective tissue disorder—Prednisone—systemic scleroderma	0.000495	0.00114	CcSEcCtD
Palonosetron—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000493	0.00114	CcSEcCtD
Palonosetron—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000492	0.00114	CcSEcCtD
Palonosetron—Dizziness—Azathioprine—systemic scleroderma	0.000491	0.00113	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000481	0.00111	CcSEcCtD
Palonosetron—Asthenia—Mycophenolic acid—systemic scleroderma	0.00048	0.00111	CcSEcCtD
Palonosetron—Diarrhoea—Leflunomide—systemic scleroderma	0.00048	0.00111	CcSEcCtD
Palonosetron—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000477	0.0011	CcSEcCtD
Palonosetron—Body temperature increased—Lisinopril—systemic scleroderma	0.000476	0.0011	CcSEcCtD
Palonosetron—Abdominal pain—Lisinopril—systemic scleroderma	0.000476	0.0011	CcSEcCtD
Palonosetron—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000474	0.00109	CcSEcCtD
Palonosetron—Pruritus—Mycophenolic acid—systemic scleroderma	0.000473	0.00109	CcSEcCtD
Palonosetron—Vomiting—Azathioprine—systemic scleroderma	0.000472	0.00109	CcSEcCtD
Palonosetron—Eye disorder—Prednisone—systemic scleroderma	0.00047	0.00109	CcSEcCtD
Palonosetron—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.00047	0.00109	CcSEcCtD
Palonosetron—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000469	0.00108	CcSEcCtD
Palonosetron—Rash—Azathioprine—systemic scleroderma	0.000468	0.00108	CcSEcCtD
Palonosetron—Dermatitis—Azathioprine—systemic scleroderma	0.000468	0.00108	CcSEcCtD
Palonosetron—Headache—Azathioprine—systemic scleroderma	0.000465	0.00107	CcSEcCtD
Palonosetron—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000464	0.00107	CcSEcCtD
Palonosetron—Dizziness—Leflunomide—systemic scleroderma	0.000463	0.00107	CcSEcCtD
Palonosetron—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000459	0.00106	CcSEcCtD
Palonosetron—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000457	0.00106	CcSEcCtD
Palonosetron—Angiopathy—Prednisone—systemic scleroderma	0.000457	0.00105	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000456	0.00105	CcSEcCtD
Palonosetron—Immune system disorder—Prednisone—systemic scleroderma	0.000455	0.00105	CcSEcCtD
Palonosetron—Pain—Mycophenolate mofetil—systemic scleroderma	0.000451	0.00104	CcSEcCtD
Palonosetron—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000451	0.00104	CcSEcCtD
Palonosetron—Arrhythmia—Prednisone—systemic scleroderma	0.00045	0.00104	CcSEcCtD
Palonosetron—Vomiting—Leflunomide—systemic scleroderma	0.000446	0.00103	CcSEcCtD
Palonosetron—Alopecia—Prednisone—systemic scleroderma	0.000445	0.00103	CcSEcCtD
Palonosetron—Hypersensitivity—Lisinopril—systemic scleroderma	0.000444	0.00102	CcSEcCtD
Palonosetron—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000443	0.00102	CcSEcCtD
Palonosetron—Dizziness—Mycophenolic acid—systemic scleroderma	0.000442	0.00102	CcSEcCtD
Palonosetron—Epistaxis—Methotrexate—systemic scleroderma	0.000442	0.00102	CcSEcCtD
Palonosetron—Rash—Leflunomide—systemic scleroderma	0.000442	0.00102	CcSEcCtD
Palonosetron—Dermatitis—Leflunomide—systemic scleroderma	0.000442	0.00102	CcSEcCtD
Palonosetron—Mental disorder—Prednisone—systemic scleroderma	0.000441	0.00102	CcSEcCtD
Palonosetron—Nausea—Azathioprine—systemic scleroderma	0.000441	0.00102	CcSEcCtD
Palonosetron—Headache—Leflunomide—systemic scleroderma	0.000439	0.00101	CcSEcCtD
Palonosetron—Erythema—Prednisone—systemic scleroderma	0.000438	0.00101	CcSEcCtD
Palonosetron—Malnutrition—Prednisone—systemic scleroderma	0.000438	0.00101	CcSEcCtD
Palonosetron—Asthenia—Lisinopril—systemic scleroderma	0.000432	0.000997	CcSEcCtD
Palonosetron—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000431	0.000996	CcSEcCtD
Palonosetron—Pruritus—Lisinopril—systemic scleroderma	0.000426	0.000983	CcSEcCtD
Palonosetron—Vomiting—Mycophenolic acid—systemic scleroderma	0.000425	0.000981	CcSEcCtD
Palonosetron—Rash—Mycophenolic acid—systemic scleroderma	0.000422	0.000973	CcSEcCtD
Palonosetron—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000421	0.000972	CcSEcCtD
Palonosetron—Headache—Mycophenolic acid—systemic scleroderma	0.000419	0.000967	CcSEcCtD
Palonosetron—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000417	0.000963	CcSEcCtD
Palonosetron—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000417	0.000963	CcSEcCtD
Palonosetron—Nausea—Leflunomide—systemic scleroderma	0.000416	0.000961	CcSEcCtD
Palonosetron—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000416	0.000959	CcSEcCtD
Palonosetron—Urethral disorder—Methotrexate—systemic scleroderma	0.000412	0.000952	CcSEcCtD
Palonosetron—Diarrhoea—Lisinopril—systemic scleroderma	0.000412	0.000951	CcSEcCtD
Palonosetron—Anaemia—Prednisone—systemic scleroderma	0.000405	0.000935	CcSEcCtD
Palonosetron—Dizziness—Lisinopril—systemic scleroderma	0.000398	0.000919	CcSEcCtD
Palonosetron—Nausea—Mycophenolic acid—systemic scleroderma	0.000397	0.000917	CcSEcCtD
Palonosetron—Eye disorder—Methotrexate—systemic scleroderma	0.000393	0.000908	CcSEcCtD
Palonosetron—Tinnitus—Methotrexate—systemic scleroderma	0.000392	0.000905	CcSEcCtD
Palonosetron—Cardiac disorder—Methotrexate—systemic scleroderma	0.00039	0.000901	CcSEcCtD
Palonosetron—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000389	0.000897	CcSEcCtD
Palonosetron—Vomiting—Lisinopril—systemic scleroderma	0.000383	0.000884	CcSEcCtD
Palonosetron—Angiopathy—Methotrexate—systemic scleroderma	0.000382	0.000881	CcSEcCtD
Palonosetron—Immune system disorder—Methotrexate—systemic scleroderma	0.00038	0.000877	CcSEcCtD
Palonosetron—Rash—Lisinopril—systemic scleroderma	0.00038	0.000876	CcSEcCtD
Palonosetron—Convulsion—Prednisone—systemic scleroderma	0.00038	0.000876	CcSEcCtD
Palonosetron—Dermatitis—Lisinopril—systemic scleroderma	0.000379	0.000876	CcSEcCtD
Palonosetron—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000379	0.000875	CcSEcCtD
Palonosetron—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000379	0.000874	CcSEcCtD
Palonosetron—Hypertension—Prednisone—systemic scleroderma	0.000378	0.000873	CcSEcCtD
Palonosetron—Chills—Methotrexate—systemic scleroderma	0.000378	0.000871	CcSEcCtD
Palonosetron—Headache—Lisinopril—systemic scleroderma	0.000377	0.000871	CcSEcCtD
Palonosetron—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000373	0.000862	CcSEcCtD
Palonosetron—Myalgia—Prednisone—systemic scleroderma	0.000373	0.000861	CcSEcCtD
Palonosetron—Arthralgia—Prednisone—systemic scleroderma	0.000373	0.000861	CcSEcCtD
Palonosetron—Anxiety—Prednisone—systemic scleroderma	0.000372	0.000858	CcSEcCtD
Palonosetron—Alopecia—Methotrexate—systemic scleroderma	0.000372	0.000858	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000371	0.000855	CcSEcCtD
Palonosetron—Discomfort—Prednisone—systemic scleroderma	0.000369	0.000851	CcSEcCtD
Palonosetron—Mental disorder—Methotrexate—systemic scleroderma	0.000369	0.000851	CcSEcCtD
Palonosetron—Erythema—Methotrexate—systemic scleroderma	0.000366	0.000845	CcSEcCtD
Palonosetron—Malnutrition—Methotrexate—systemic scleroderma	0.000366	0.000845	CcSEcCtD
Palonosetron—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000361	0.000833	CcSEcCtD
Palonosetron—Dysgeusia—Methotrexate—systemic scleroderma	0.000359	0.000828	CcSEcCtD
Palonosetron—Nausea—Lisinopril—systemic scleroderma	0.000358	0.000826	CcSEcCtD
Palonosetron—Anaphylactic shock—Prednisone—systemic scleroderma	0.000358	0.000826	CcSEcCtD
Palonosetron—Infection—Prednisone—systemic scleroderma	0.000355	0.00082	CcSEcCtD
Palonosetron—Shock—Prednisone—systemic scleroderma	0.000352	0.000812	CcSEcCtD
Palonosetron—Nervous system disorder—Prednisone—systemic scleroderma	0.000351	0.00081	CcSEcCtD
Palonosetron—Tachycardia—Prednisone—systemic scleroderma	0.000349	0.000806	CcSEcCtD
Palonosetron—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000349	0.000805	CcSEcCtD
Palonosetron—Skin disorder—Prednisone—systemic scleroderma	0.000347	0.000802	CcSEcCtD
Palonosetron—Anorexia—Prednisone—systemic scleroderma	0.000341	0.000787	CcSEcCtD
Palonosetron—Anaemia—Methotrexate—systemic scleroderma	0.000339	0.000781	CcSEcCtD
Palonosetron—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000336	0.000774	CcSEcCtD
Palonosetron—Rash—Mycophenolate mofetil—systemic scleroderma	0.000333	0.000768	CcSEcCtD
Palonosetron—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000332	0.000767	CcSEcCtD
Palonosetron—Headache—Mycophenolate mofetil—systemic scleroderma	0.000331	0.000763	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000326	0.000752	CcSEcCtD
Palonosetron—Insomnia—Prednisone—systemic scleroderma	0.000324	0.000747	CcSEcCtD
Palonosetron—Paraesthesia—Prednisone—systemic scleroderma	0.000321	0.000741	CcSEcCtD
Palonosetron—Convulsion—Methotrexate—systemic scleroderma	0.000317	0.000732	CcSEcCtD
Palonosetron—Dyspepsia—Prednisone—systemic scleroderma	0.000315	0.000727	CcSEcCtD
Palonosetron—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000313	0.000723	CcSEcCtD
Palonosetron—Myalgia—Methotrexate—systemic scleroderma	0.000312	0.00072	CcSEcCtD
Palonosetron—Arthralgia—Methotrexate—systemic scleroderma	0.000312	0.00072	CcSEcCtD
Palonosetron—Decreased appetite—Prednisone—systemic scleroderma	0.000311	0.000718	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.00031	0.000715	CcSEcCtD
Palonosetron—Fatigue—Prednisone—systemic scleroderma	0.000308	0.000712	CcSEcCtD
Palonosetron—Discomfort—Methotrexate—systemic scleroderma	0.000308	0.000711	CcSEcCtD
Palonosetron—Constipation—Prednisone—systemic scleroderma	0.000306	0.000706	CcSEcCtD
Palonosetron—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000299	0.00069	CcSEcCtD
Palonosetron—Infection—Methotrexate—systemic scleroderma	0.000297	0.000685	CcSEcCtD
Palonosetron—Nervous system disorder—Methotrexate—systemic scleroderma	0.000293	0.000677	CcSEcCtD
Palonosetron—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000292	0.000675	CcSEcCtD
Palonosetron—Skin disorder—Methotrexate—systemic scleroderma	0.00029	0.00067	CcSEcCtD
Palonosetron—Anorexia—Methotrexate—systemic scleroderma	0.000285	0.000658	CcSEcCtD
Palonosetron—Abdominal pain—Prednisone—systemic scleroderma	0.000283	0.000653	CcSEcCtD
Palonosetron—Body temperature increased—Prednisone—systemic scleroderma	0.000283	0.000653	CcSEcCtD
Palonosetron—Hypotension—Methotrexate—systemic scleroderma	0.000279	0.000645	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000272	0.000629	CcSEcCtD
Palonosetron—Insomnia—Methotrexate—systemic scleroderma	0.00027	0.000624	CcSEcCtD
Palonosetron—Paraesthesia—Methotrexate—systemic scleroderma	0.000268	0.00062	CcSEcCtD
Palonosetron—Dyspnoea—Methotrexate—systemic scleroderma	0.000267	0.000615	CcSEcCtD
Palonosetron—Somnolence—Methotrexate—systemic scleroderma	0.000266	0.000613	CcSEcCtD
Palonosetron—Hypersensitivity—Prednisone—systemic scleroderma	0.000264	0.000608	CcSEcCtD
Palonosetron—Dyspepsia—Methotrexate—systemic scleroderma	0.000263	0.000607	CcSEcCtD
Palonosetron—Decreased appetite—Methotrexate—systemic scleroderma	0.00026	0.0006	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000258	0.000596	CcSEcCtD
Palonosetron—Fatigue—Methotrexate—systemic scleroderma	0.000258	0.000595	CcSEcCtD
Palonosetron—Asthenia—Prednisone—systemic scleroderma	0.000257	0.000592	CcSEcCtD
Palonosetron—Pain—Methotrexate—systemic scleroderma	0.000256	0.00059	CcSEcCtD
Palonosetron—Pruritus—Prednisone—systemic scleroderma	0.000253	0.000584	CcSEcCtD
Palonosetron—Diarrhoea—Prednisone—systemic scleroderma	0.000245	0.000565	CcSEcCtD
Palonosetron—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000244	0.000564	CcSEcCtD
Palonosetron—Dizziness—Prednisone—systemic scleroderma	0.000237	0.000546	CcSEcCtD
Palonosetron—Abdominal pain—Methotrexate—systemic scleroderma	0.000236	0.000545	CcSEcCtD
Palonosetron—Body temperature increased—Methotrexate—systemic scleroderma	0.000236	0.000545	CcSEcCtD
Palonosetron—Vomiting—Prednisone—systemic scleroderma	0.000227	0.000525	CcSEcCtD
Palonosetron—Rash—Prednisone—systemic scleroderma	0.000226	0.000521	CcSEcCtD
Palonosetron—Dermatitis—Prednisone—systemic scleroderma	0.000225	0.00052	CcSEcCtD
Palonosetron—Headache—Prednisone—systemic scleroderma	0.000224	0.000517	CcSEcCtD
Palonosetron—Hypersensitivity—Methotrexate—systemic scleroderma	0.00022	0.000508	CcSEcCtD
Palonosetron—Asthenia—Methotrexate—systemic scleroderma	0.000214	0.000495	CcSEcCtD
Palonosetron—Nausea—Prednisone—systemic scleroderma	0.000212	0.00049	CcSEcCtD
Palonosetron—Pruritus—Methotrexate—systemic scleroderma	0.000211	0.000488	CcSEcCtD
Palonosetron—Diarrhoea—Methotrexate—systemic scleroderma	0.000205	0.000472	CcSEcCtD
Palonosetron—Dizziness—Methotrexate—systemic scleroderma	0.000198	0.000456	CcSEcCtD
Palonosetron—Vomiting—Methotrexate—systemic scleroderma	0.00019	0.000439	CcSEcCtD
Palonosetron—Rash—Methotrexate—systemic scleroderma	0.000188	0.000435	CcSEcCtD
Palonosetron—Dermatitis—Methotrexate—systemic scleroderma	0.000188	0.000435	CcSEcCtD
Palonosetron—Headache—Methotrexate—systemic scleroderma	0.000187	0.000432	CcSEcCtD
Palonosetron—Nausea—Methotrexate—systemic scleroderma	0.000178	0.00041	CcSEcCtD
